# AgomAb Therapeutics NV (AGMB)

Source: https://www.quantisnow.com/company/AGMB
Generated: 2026-11-12T01:47:29.054Z

- Ticker: AGMB
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- IPO year: 2026
- SEC CIK: 0002020932

## Latest AGMB news and filings

- 2026-11-06 11:39 UTC [Insider Buy] [Director Epstein David R bought $103,500 worth of shares (15,000 units at $6.90), increasing direct ownership by 60% to 40,000 units (SEC Form 4)](https://www.quantisnow.com/insight/director-epstein-david-r-bought-103500-worth-of-shares-15000-6777845)
- 2026-11-04 21:05 UTC [Conference Announcement] [Agomab to Participate in Upcoming Investor Conferences](https://www.quantisnow.com/insight/agomab-to-participate-in-upcoming-investor-conferences-6772276)
- 2026-10-22 12:14 UTC [Insider Buy] [Director Epstein David R bought $88,800 worth of shares (10,000 units at $8.88) (SEC Form 4)](https://www.quantisnow.com/insight/director-epstein-david-r-bought-88800-worth-of-shares-10000-6754529)
- 2026-10-13 21:18 UTC [SEC Form 6-K] [SEC Form 6-K filed by AgomAb Therapeutics NV](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-agomab-therapeutics-nv-6745456)
- 2026-10-13 20:05 UTC [Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease](https://www.quantisnow.com/insight/agomab-announces-first-patient-dosed-in-global-nov-era-phase-2b-6744937)
- 2026-10-09 12:01 UTC [Insider Buy] [Director Epstein David R bought $44,500 worth of shares (5,000 units at $8.90) (SEC Form 4)](https://www.quantisnow.com/insight/director-epstein-david-r-bought-44500-worth-of-shares-5000-6742410)
- 2026-10-08 20:05 UTC [Agomab to Present STENOVA Open-Label Extension Data of Ontunisertib at UEG Week 2026 and Host Scientific Symposium on Fibro-Inflammation](https://www.quantisnow.com/insight/agomab-to-present-stenova-open-label-extension-data-of-ontunisertib-at-6741724)
- 2026-10-07 12:57 UTC [Insider Buy] [Director Epstein David R bought $86,350 worth of shares (10,000 units at $8.64) (SEC Form 4)](https://www.quantisnow.com/insight/director-epstein-david-r-bought-86350-worth-of-shares-10000-6739963)
- 2026-10-07 12:47 UTC [Insider Buy] [Chief Financial Officer Kemula Pierre Thadee Victor bought $85,940 worth of shares (10,000 units at $8.59) (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-kemula-pierre-thadee-victor-bought-85940-worth-6739907)
- 2026-10-07 12:06 UTC [Insider Buy] [Chief Executive Officer Knotnerus Tim Jasper bought $94,380 worth of shares (11,000 units at $8.58) (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-knotnerus-tim-jasper-bought-94380-worth-of-6739784)
- 2026-10-01 10:42 UTC [SEC Form 6-K] [SEC Form 6-K filed by AgomAb Therapeutics NV](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-agomab-therapeutics-nv-6731278)
- 2026-10-01 10:30 UTC [Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease](https://www.quantisnow.com/insight/agomab-reports-positive-topline-data-from-stenova-open-label-extension-study-6731261)
- 2026-09-15 20:06 UTC [SEC Form 4] [SEC Form 4 filed by Director Garcia Marino](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-garcia-marino-6716066)
- 2026-09-15 20:06 UTC [SEC Form 4] [SEC Form 4 filed by Director Patel Naimish](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-patel-naimish-6716060)
- 2026-09-15 20:05 UTC [SEC Form 3] [SEC Form 3 filed by new insider Patel Naimish](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-patel-naimish-6716055)
- 2026-09-15 20:05 UTC [SEC Form 3] [SEC Form 3 filed by new insider Garcia Marino](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-garcia-marino-6716050)
- 2026-09-14 20:14 UTC [SEC Form 6-K] [SEC Form 6-K filed by AgomAb Therapeutics NV](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-agomab-therapeutics-nv-6714527)
- 2026-09-14 20:05 UTC [Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study](https://www.quantisnow.com/insight/agomab-announces-positive-phase-1-results-for-agmb-447-in-patients-6714388)
- 2026-09-11 21:02 UTC [SEC Form 6-K] [SEC Form 6-K filed by AgomAb Therapeutics NV](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-agomab-therapeutics-nv-6713258)
- 2026-09-11 20:05 UTC [Public Offering] [Agomab Announces Appointments of Marino Garcia and  Dr. Naimish Patel to Board of Directors](https://www.quantisnow.com/insight/agomab-announces-appointments-of-marino-garcia-and-dr-naimish-patel-6712899)
- 2026-09-03 20:05 UTC [Conference Announcement] [Agomab to Participate in Upcoming Investor Conferences](https://www.quantisnow.com/insight/agomab-to-participate-in-upcoming-investor-conferences-6704944)
- 2026-08-25 12:43 UTC [Analyst Coverage Initiated] [Piper Sandler initiated coverage on AgomAb Therapeutics NV with a new price target](https://www.quantisnow.com/insight/piper-sandler-initiated-coverage-on-agomab-therapeutics-nv-with-a-6693734)
- 2026-08-19 12:20 UTC [Analyst Coverage Initiated] [Cantor Fitzgerald initiated coverage on AgomAb Therapeutics NV](https://www.quantisnow.com/insight/cantor-fitzgerald-initiated-coverage-on-agomab-therapeutics-nv-6687868)
- 2026-08-10 20:17 UTC [SEC Form 6-K] [SEC Form 6-K filed by AgomAb Therapeutics NV](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-agomab-therapeutics-nv-6673853)
- 2026-08-10 20:07 UTC [Public Offering] [Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors](https://www.quantisnow.com/insight/agomab-announces-proposed-appointments-of-marino-garcia-and-dr-naimish-6673639)
- 2026-08-06 20:06 UTC [SEC Form 6-K] [SEC Form 6-K filed by AgomAb Therapeutics NV](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-agomab-therapeutics-nv-6668915)
- 2026-08-06 20:01 UTC [Public Offering] [Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook](https://www.quantisnow.com/insight/agomab-reports-half-year-2026-financial-results-and-confirms-2026-6668531)
- 2026-07-23 12:28 UTC [Analyst Coverage Initiated] [B. Riley Securities initiated coverage on AgomAb Therapeutics NV with a new price target](https://www.quantisnow.com/insight/b-riley-securities-initiated-coverage-on-agomab-therapeutics-nv-with-6646425)
- 2026-06-23 20:13 UTC [SEC Form 6-K] [SEC Form 6-K filed by AgomAb Therapeutics NV](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-agomab-therapeutics-nv-6612561)
- 2026-06-23 20:05 UTC [Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease](https://www.quantisnow.com/insight/agomab-announces-design-of-nov-era-phase-2b-study-with-ontunisertib-6612432)
- 2026-06-22 13:13 UTC [Analyst Coverage Initiated] [H.C. Wainwright initiated coverage on AgomAb Therapeutics NV with a new price target](https://www.quantisnow.com/insight/hc-wainwright-initiated-coverage-on-agomab-therapeutics-nv-with-a-6610295)
- 2026-05-27 11:12 UTC [SEC Form 6-K] [SEC Form 6-K filed by AgomAb Therapeutics NV](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-agomab-therapeutics-nv-6573789)
- 2026-05-27 09:00 UTC [Agomab Announces Results of Annual General Meeting](https://www.quantisnow.com/insight/agomab-announces-results-of-annual-general-meeting-6573575)
- 2026-05-15 20:45 UTC [SEC Form SCHEDULE 13G filed by AgomAb Therapeutics NV](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-agomab-therapeutics-nv-6558054)
- 2026-05-15 17:14 UTC [SEC Form SCHEDULE 13G filed by AgomAb Therapeutics NV](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-agomab-therapeutics-nv-6556676)
- 2026-05-14 11:30 UTC [Conference Announcement] [Agomab to Participate in Upcoming Conferences](https://www.quantisnow.com/insight/agomab-to-participate-in-upcoming-conferences-6552371)
- 2026-05-06 10:00 UTC [SEC Form SCHEDULE 13G filed by AgomAb Therapeutics NV](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-agomab-therapeutics-nv-6533737)
- 2026-04-24 20:22 UTC [SEC Form 6-K] [SEC Form 6-K filed by AgomAb Therapeutics NV](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-agomab-therapeutics-nv-6514640)
- 2026-04-23 22:14 UTC [Public Offering] [Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook](https://www.quantisnow.com/insight/agomab-reports-full-year-2025-financial-results-and-confirms-2026-6513253)
- 2026-04-23 21:17 UTC [SEC Form 20-F filed by AgomAb Therapeutics NV](https://www.quantisnow.com/insight/sec-form-20-f-filed-by-agomab-therapeutics-nv-6513167)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/AGMB
- Earnings history: https://www.quantisnow.com/earnings/AGMB
- Dividend history: https://www.quantisnow.com/dividends/AGMB
- Insider transactions: https://www.quantisnow.com/insiders/AGMB
- Options chain: https://www.quantisnow.com/options/AGMB
- SEC 8-K filings only: https://www.quantisnow.com/company/AGMB/8-k
- RSS and alerts for AGMB: https://www.quantisnow.com/docs/rss-feeds.md